New Opportunities, New Challenges: FDA Elaborates on use of Digital Health in Drug and Biological Product Development | Reed Smith

Skip to content

Note: This is Part 1 in a series of blog posts on developments from the U.S. Food and Drug Administration (“FDA”) regarding its commitments set forth under the Prescription Drug Under Fee Act Reauthorization Performance Goals and Clinical Trial…

Source: www.jdsupra.com – Read more